Kuraray (3405) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jun, 2025Executive summary
Net sales rose 7.9% year-over-year to ¥411.2B, operating income up 11% to ¥45.5B, and net income up 39.4% to ¥30.4B, all setting interim records, driven by sales volume growth and yen depreciation.
All financial KPIs improved, with ROIC at 7.5% and EBITDA margin at 21.2% for 1H FY2024.
Upward revision of full-year forecasts for net sales, operating income, and net income.
Sales volume expanded across many businesses despite global economic uncertainty and geopolitical risks.
Financial highlights
1H FY2024 net sales ¥411.2B (+¥30.2B), operating income ¥45.5B (+¥4.5B), net income ¥30.4B (+¥8.6B) year-over-year.
Gross profit increased to ¥133.4B from ¥119.8B year-over-year; operating margin improved to 11.1%.
Equity ratio improved to 60.4% as of June 30, 2024; net assets rose to ¥819.4B.
Operating cash flow ¥63.7B, free cash flow ¥27.9B, CAPEX ¥34.9B in 1H FY2024.
Cash and cash equivalents at period-end were ¥126.2B, up from ¥110.3B a year earlier.
Outlook and guidance
FY2024 net sales forecast raised to ¥850.0B (+¥69.1B vs. FY2023), operating income to ¥89.0B (+¥13.5B), net income to ¥55.0B (+¥12.6B).
Dividend forecast increased by ¥4 to ¥54 per share for FY2024.
Share buyback of up to 15M shares and ¥20.0B planned, targeting a total return ratio of around 68%.
CAPEX for FY2024 set at ¥130.0B (decision basis), R&D expenses at ¥27.0B.
Latest events from Kuraray
- FY2025 profit dropped on impairments, but FY2026 forecasts a strong rebound and higher dividends.3405
Q4 202610 Feb 2026 - SentryGlas® dominates structural glass with high performance and sustainability, driving global growth.3405
Investor Update19 Dec 2025 - Profits fell over 50% year-over-year; forecasts cut and major share buyback completed.3405
Q3 202612 Nov 2025 - Profits and sales fell in 1H FY2025, but portfolio restructuring and buybacks advanced.3405
Q2 20268 Aug 2025 - High-performance PVOH products and cell culture solutions drive robust global growth outlook.3405
Investor Day 202519 Jun 2025 - Profits and shareholder returns rose, with robust guidance despite lower sales forecast.3405
Q3 202513 Jun 2025 - Sales up, profits down; full-year outlook steady, major share buyback planned.3405
Q1 20266 Jun 2025 - Record sales and operating income, but net income fell on extraordinary losses; profit recovery forecast.3405
Q4 20255 Jun 2025